Why Levothyroxine Stops Working (The Conversion Problem Nobody Tests)

Most people on levothyroxine are told their thyroid problem is solved once their TSH comes back in range. Their prescription gets refilled, their doctor nods, and the appointment ends. But somewhere between 12 and 40 percent of those patients still feel exhausted, foggy, cold, and heavy despite that normal lab value, and the reason has almost nothing to do with the thyroid itself.

To understand why, you need to see the whole system first.

Your thyroid gland produces two hormones: T4 and T3. T3 is the active form, meaning it is the one that actually binds to receptors in your cells and drives your metabolism, your energy production, your mood regulation, and your body temperature. T4 is largely inactive on its own. It is more like a storage form, a precursor that your body has to convert before it can be used.

Here is the part most people never hear: your thyroid only makes about 20 percent of the T3 circulating in your blood. The other 80 percent comes from conversion happening in your liver, your kidneys, and your gut.

So when levothyroxine, which is synthetic T4, gets prescribed, the entire treatment model rests on one assumption: that your body will handle that conversion on its own. The drug delivers the raw material, and your body is supposed to do the rest.

That conversion happens through a family of enzymes called deiodinases, which are proteins that physically remove an iodine atom from T4 to produce T3. Think of T4 as a locked package and deiodinases as the key. Without them, the package never opens, and the contents never reach your cells.

The problem is that TSH, which stands for thyroid stimulating hormone, does not measure whether that conversion is happening. TSH is produced by the pituitary gland at the base of your brain, and it reflects how much T4 the pituitary is sensing in circulation. When T4 levels look adequate to the pituitary, TSH drops into the normal range. The test shows green, the appointment ends, and nobody checks whether that T4 is actually becoming T3 downstream.

A 2022 review in The Lancet Diabetes and Endocrinology pointed to studies showing that patients on levothyroxine with completely normal TSH had T3 to T4 ratios 15 to 20 percent lower than people with healthy, functioning thyroids. The pituitary was satisfied. The rest of the body was running short.

So why would conversion fail in the first place?

The deiodinase enzymes are what scientists call selenoproteins, which means they require selenium as a structural component to function at all. Selenium is a trace mineral, and its concentration in food depends heavily on the selenium content of the soil it was grown in, which varies dramatically by region and has declined in many agricultural areas over time. When selenium is insufficient, deiodinase activity drops, T4 stacks up unused, and T3 production falls. A 2021 study in Clinical Pediatric Endocrinology found that selenium deficient patients showed measurably elevated free T4 to T3 ratios, which is exactly what you would expect when the conversion step is impaired.

Chronic inflammation is a second brake on the system. Inflammatory signals, particularly cytokines that circulate during ongoing immune activation, suppress deiodinase gene expression. This is relevant for anyone with Hashimoto's thyroiditis, which is the autoimmune condition that causes most cases of hypothyroidism in the developed world. The Hashimoto's immune response attacks the thyroid tissue directly, which reduces that 20 percent of T3 the gland makes itself. But the inflammation also downregulates the conversion enzymes, which undermines the 80 percent from peripheral conversion at the same time. The disease impairs both pathways simultaneously.

Liver dysfunction adds another layer, because the liver is one of the primary sites where T4 to T3 conversion happens. Even mild, subclinical liver stress from metabolic dysfunction, alcohol, or medication burden can reduce the liver's contribution to that conversion process.

And then there is genetics. Between 12 and 36 percent of people carry a variant in a gene called DIO2, which codes directly for one of those deiodinase enzymes. A 2009 study in the Journal of Clinical Endocrinology and Metabolism found that people with this variant had worse psychological wellbeing at baseline and responded significantly better to combination T4 plus T3 therapy than to T4 alone. Their bodies were structurally less efficient at converting, and no amount of optimizing their TSH would change that.

This is the part that matters practically. If you are on levothyroxine and still experiencing symptoms, the first thing to ask your doctor is to run a free T3 level alongside your TSH. Free T3 measures the unbound, bioavailable form of the active hormone in your blood. It tells you whether the conversion step is actually completing, not just whether your pituitary is content with the T4 it sees.

If free T3 comes back low or low-normal in someone who is still symptomatic, that is a conversion problem, and there are two directions to explore. The first is addressing the inputs that support deiodinase function, with selenium being the most direct. The research suggests 200 micrograms per day as a therapeutic dose for thyroid support, and this is worth discussing with your provider rather than self-supplementing, because selenium has a relatively narrow window between adequate and toxic intake. The second direction, which requires a willing physician, is considering a medication that contains T3 directly, either liothyronine alone or a combination product, rather than relying entirely on your body's conversion capacity.

A 2019 survey published in Thyroid found that among hypothyroid patients treated with levothyroxine, dissatisfaction rates were high and many patients expressed preference for combination therapy. The gap between labs and lived experience is not imaginary, and it is not psychological. It is mechanistic.

Levothyroxine is not a broken drug. It works exactly as designed. The design assumption is that conversion happens reliably, and for many people it does. But for a meaningful portion of patients, the enzyme activity is blunted by selenium deficiency, inflammation, a genetic variant, liver stress, or some combination of all of them, and no one ever checks.

Treating a TSH value is not the same as treating a person. The hormone your cells actually use is T3, and whether your body is producing enough of it requires a different test than the one most doctors order.

---

References

1. Bianco AC, Kim BW. Deiodinases: implications of the local control of thyroid hormone action. J Clin Invest. 2006;11610:2571-2579. PMID: 17016550. Source
2. Endotext NCBI Bookshelf. Thyroid Hormone Synthesis and Secretion: "The thyroid gland produces approximately 20% of total daily T3 production, with the remaining 80% arising from peripheral deiodination of T4." Source
3. Salvatore D, Porcelli T, Ettleson MD, Bianco AC. The relevance of T3 in the management of hypothyroidism. Lancet Diabetes Endocrinol. 2022;10(5):366-372. DOI: 10.1016/S2213-8587(22)00004-3.
4. Peterson SJ, Cappola AR, Castro MR, et al. An online survey of hypothyroid patients demonstrates prominent dissatisfaction. Thyroid. 2019;295:707-721. PMID: 29620972. Source
5. Panicker V, Saravanan P, Vaidya B, et al. Common variation in the DIO2 gene predicts baseline psychological well-being and response to combination thyroxine plus triiodothyronine therapy. JCEM. 2009;945:1623-1629. PMID: 19190113. Source
6. Kobayashi R, Hasegawa Y, Kawaguchi T, et al. Thyroid function in patients with selenium deficiency exhibits high free T4 to T3 ratio. Clin Pediatr Endocrinol. 2021;30(1):19-26. DOI: 10.1297/cpe.30.19.
7. Ventura M, Melo M, Carrilho F. Selenium and thyroid disease: from pathophysiology to treatment. Int J Endocrinol. 2017;2017:1297658. PMID: 28255299. Source

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness